Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

ClinicalTrials.gov ID: NCT04170283

Public ClinicalTrials.gov record NCT04170283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study. Participants continued receiving zanubrutinib if they were still benefiting from it, or they might have taken part in long-term follow-up after treatment. Information collected in this study will help health authorities better understand the long-term effects of zanubrutinib.

Study identification

NCT ID
NCT04170283
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
BeOne Medicines
Industry
Enrollment
955 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 15, 2020
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026
Last update posted
Aug 27, 2026

2020 – 2026

United States locations

U.S. sites
26
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
Banner Md Anderson Cancer Center Gilbert Arizona 85234
Carti Cancer Center Little Rock Arkansas 72205
Rocky Mountain Cancer Centers Centennial Centennial Colorado 80112
Colorado Blood Cancer Institute Denver Colorado 80218
Florida Cancer Specialists Fort Myers Fort Myers Florida 33916
Scri Florida Cancer Specialists North St. Petersburg Florida 33705
Dana Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Health System Ann Arbor Michigan 48109
Mayo Clinic Rochester Rochester Minnesota 55905
Forrest General Hospital Cancer Center Hattiesburg Mississippi 39401
University of Nebraska Medical Center Omaha Nebraska 68198
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
Summit Medical Group Florham Park New Jersey 07932
Atlantic Health System Morristown New Jersey 07960
Optum Medical Care, Pc. Westbury New York 11590
Duke University Hospital Durham North Carolina 27705
Oncology Associates of Oregon Willamette Valley Cancer Center Eugene Oregon 97401
Oregon Health and Science University Portland Oregon 97239
Scri Tennessee Oncology Chattanooga Chattanooga Tennessee 37404
Tennessee Oncology Nashville Tennessee 37205
Texas Oncology Fort Worth Cancer Center Fort Worth Texas 76104-2150
The University of Texas Md Anderson Cancer Center Houston Texas 77030-4009
Texas Oncology San Antonio Medical Center Usor San Antonio Texas 78240
Oncology and Hematology Associates of Southwest Virginia, Inc Roanoke Virginia 24014
University of Washington Seattle Cancer Alliance Seattle Washington 98185
Medical Oncology Associates Spokane Washington 99208

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 127 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04170283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 27, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04170283 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →